THE RENIN SYSTEM IN CARDIOVASCULAR AND ELECTROLYTE PHYSIOLOGY AND IN MEDICINE 366 SELECTED REFERENCES FROM OVER 900 PAPERS

1. Laragh JH: The effect of potassium chloride on hyponatremia. J. Clin. Invest. 33: 807-8l8, l954.

2. Laragh JH, Capeci NE: Effect of administration of potassium chloride on the serum sodium and potassium concentration. Am. J. Physiol. l80: 539-544, l955.

3. Laragh JH, Van Dyke HB, Jacobson J, Adamson Jr. K, Engel SL: The experimental production of ascites in the dog with diabetes insipidus. J. Clin. Invest. 35: 897-903, l956.

4. Jacobson J, Laragh JH, McAllister FF: The experimental production of a reversible state of chronic progressive edema. Surg. Forum 7: 45-47, l956.

5. Laragh JH, Gilman A: Mechanisms of edema formation and principles of management. Combined Staff Clinic. Am. J. Med. 2l: 423-44l, l956.

6. Laragh JH, Stoerk HC: A study of the mechanism of secretion of the sodium-retaining hormone (aldosterone). Plasma K+ stimulates aldosterone secretion. J. Clin. Invest. 36: 383-392, l957.

7. Laragh JH, Heinemann HO, Demartini FE: The effect of chlorothiazide on electrolyte transport in man. Its use in the treatment of edema of congestive heart failure, nephrosis and cirrhosis. JAMA l66: l45-l52, l958.

8. Anderson HM, Laragh JH: Renal excretion of potassium in normal and sodium depleted dogs. J. Clin. Invest. 37: 323-33l, l958.

9. Ulick S, Laragh JH, Lieberman S: The isolation of a urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man. Trans. Assoc. Am. Physicians 7l: 225-235, l958.

10. Bradley SE, Laragh JH, Wheeler HO, MacDowell M, Oliver J: Correlation of structure and function in the nephron population. Trans. Assoc. Am. Physicians 72: 294-304, l959.

11. Laragh JH: The use of diuretics in the treatment of congestive heart failure. Postgrad. Med. 25: 528-534, l959.

12. Heinemann HO, Demartini FE, Laragh JH: The effect of chlorothiazide on renal excretion of electrolytes and free water. Am. J. Med. 26: 853-86l, l959.

13. Januszewicz W, Heinemann HO, Demartini FE, Laragh JH: A clinical study of the effects of hydrochlorothiazide on renal excretion of electrolytes and free water. N. Engl. J. Med. 26l: 264-269, l959.

14. Laragh JH: Comments on the control of aldosterone secretion. Proceedings of the 1958 Laurentian Hormone Conference. Recent Progress in Hormone Research XV, pp 308-310 and 335-336, Acemedic Press, New York and London, 1959.

15. Laragh JH, Ulick S, Januszewicz W, Deming WB, Kelly WG, Lieberman S: Aldosterone secretion and primary and malignant hypertension. J. Clin. Invest. 39: l09l-ll06, l960.

16. Laragh JH, Ulick S, Januszewicz V, Kelly WG, Lieberman S: Electrolyte metabolism and aldosterone secretion in benign and malignant hypertension. Ann. Intern. Med. 53: 259-272,1960.

17. Laragh JH, Angers M, Kelly WG, Lieberman S: Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II and others on the secretory rate of aldosterone in man. JAMA l74: 234-240, l960.

18. Laragh JH: The role of aldosterone in man: Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. JAMA l74: 293-295, l960.

19. Laragh JH: Proceedings of the 1960 Laurentian Hormone Conference. Demonstrations of the unique stimulation of aldosterone release by angiotensin infusion and not by other pressor substances in normal humans. Recent Prog. Horm. Res. 17: 348-352. Academic Press, New York and London 1961.

20. Laragh JH: Relation of aldosterone secretion to hypertensive vascular disease. Circ. Res. 9: 792-804, 1961.

21. Sonnenblick EH, Cannon PJ, Laragh JH: The nature of action of intravenous aldosterone: Evidence for a role of the hormone in urinary dilution. J. Clin. Invest. 40: 903-913, 1961.
22. Bradley SE, Laragh JH, Wheeler HO, MacDowell M, Oliver J: Correlation of structure and function in the handling of glucose by the nephrons of the canine kidney. J. Clin. Invest. 40: 1113-1131, 1961.

23. Christy NP, Laragh JH: Pathogenesis of hypokalemic alkalosis in Cushing's Syndrome. N. Engl. J. Med. 265: 1083-1088, 1961.

24. Laragh JH: On the control of aldosterone secretion, pp 348-352; and on primary aldosteronism, pp 433-434. Proceedings of 1960 Laurentian Hormone Conference. Recent Progress in Hormone Research XVII, academic Press, New York and London, 1961.

25. Laragh JH: The mode of action and use of chlorothiazide and related compounds. Circulation 26: 121-132, 1962.

26. Laragh JH: Interrelationships between angiotensin, norepinephrine, epinephrine, aldosterone secretion and electrolyte metabolism in man. Circ. 25:203-211, 1962.

27. Demartini FE, Wheaton EA, Healey LA, Laragh JH: Effect of chlorothiazide on the renal excretion and uric aid. Am. J. Med. 32: 572-577, 1962.

28. Laragh JH: Hormones and pathogenesis of congestive heart failure: vasopressin, aldosterone and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and cirrhosis. Circ. 25:1015-1023, 1962.

29. Greenough III WB, Sonnenblick EH, Januszewick V, Laragh JH: Correction of hyperaldosteronism and of massive fluid retention of unknown cause by sympathomimetic agents. Am. J. Med.

30. Laragh JH, Cannon PJ: Endocrine factors in congestive heart failure: vasopressin, aldosterone and angiotensin. Med. Clin. North Am. 46:1471-1495, 1962.

31. Laragh JH, Cannon PJ, Ames RP: Aldosterone secretion and various forms of hypertensive vascular disease. Ann. Intern. Med. 59: ll7-l20, l963.

32. Laragh JH, Cannon PJ, Bentzel CJ, Sicinski AM, Meltzer JI: Angiotensin II, norepinephrine and the renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J. Clin. Invest. 42: ll79-ll92, l963.

33. Cannon PJ, Ames RP, Laragh JH: Methylenebutyryl phenoxyacetic acid. Novel and potent natriuretic and diuretic agent. J.A.M.A. 185:854-863, 1963.

34. Demartini FE, Cannon PJ, Stason WB, Laragh JH: Latic acid metabolism in hypertensive patinets. Science. 148: 1482-1484,1964.

35. Laragh JH, Cannon PJ, Ames RP: Interaction between aldosterone secretion, sodium and potassium balance, and angitoensin activity in man. Studies in hypertension and cirrhosis. Can. Med. Assoc. J. 90:248-256, 1964

36. Laragh JH, Sealey JE, Klein PD. The presence and effect of isotope fractionation in isotope dilution analysis: a factor in the measurement of aldosterone secretory rates in man. In: Radiochemical Methods of Analysis, Vol. 2, Vienna; International Atomic Energy Agency, pp 353 370,1965

37. Borkowski AJ, Howards SS, Laragh JH: Angiotensin and electrolyte excretion in renovascular hypertension. Am. J. Physiol. 208: 1087-1092, 1965.

38. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH: Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J. Clin. Invest. 44: ll7l-ll86, l965.

39. Cannon PJ. Heinemann HO, Stason WB, Laragh JH: Ethacrynic acid. Effectiveness and mode of diuretic action in man. Circ. 31:5-18, 1965.

40. Cannon PJ, Heinemann HO, Albert MS, Laragh JH, Winters RW: "Contraction" alkalosis after diuresis of edematous patients with ethacrynic acid. Ann. Intern. Med. 62:979-990, 1965.

41. Reid WD, Laragh JH: Sodium and potassium intake, blood pressure and pressor response to angitoensin. Proc. Soc. Exp. Biol. Med. 120: 26-29, 1965.

42. Laragh JH, Sealey JE, Sommers SC: Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects. Circ. Res. l8 & l9: Suppl I: l58-l74, l966.

43. Cannon PJ, Ames RP, Laragh JH: Relation between potassium balance and aldosterone secretion in normal subjects and in patients with hypertension or renal tubular disease. J. Clin. Invest. 45: 865-879, 1966.

44. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH: Hyperuricemia in primary and renal hypertension. N. Engl. J. Med. 275: 457-464, 1966.

45. Cannon PJ, Ames RP, Laragh JH: Indirect action of angiotensin infusion to inhibit renal tubular sodium reabsorption in dogs. Am.J. Physiol. 211: 1021-1030, 1966.

46. Stason WB, Cannon PJ, Heinemann HO, Laragh JH: Furosemide: A clinical evaluation of its diuretic action. Circ. 34: 910-920, 1966.

47. Sealey JE, Gerten JN, Ledingham JGG, Laragh JH: The inhibition of renin by heparin. J Clin Endocrinol Metab 27: 699 705, 1967.

48. Laragh JH, Sealey JE, Ledingham JGG, Newton MA: Oral contraceptives, renin, aldosterone and high blood pressure. J.A. M.A. 201: 918 922,1967.

49. Newton MA, Sealey JE, Ledingham JGG, Laragh JH: High blood pressure and oral contraceptives: studies of renin, angiotensinogen and aldosterone. In: Hypertension XVI. Proc. Council for High Blood Pressure Research of the American Heart Assoc, Cleveland, Ohio, pp 51 61, 1967.

50. Laragh JH, Ledingham JGG, Sommers SC: Secondary aldosteronism and reduced plasma renin in hypertensive disease. Trans. Assoc. Amer. Physicians 80: l68-l82, l967.

51. Laragh JH: The proper use of newer diuretics. Ann. Intern. Med. 67: 606-613, 1967.

52. Ledingham JGG, Bull MB, Laragh JH: The meaning of aldosteronism in hypertensive disease. Circ. Res. 20 & 2l: Suppl II: 177-186, 1967.

53. Laragh JH: Renin, angiotensin, aldosterone and hormonal regulation of arterial pressure and salt balance. Introductory remarks for the Physiology Society Symposium. Fed. Proc. 26:39-69, 1967.

54. Cannon PJ, Leeming JM, Sommers SC, Winters RW, Laragh JH: Juxtaglomerular cell hyperplasia and secondary hyperaldosteronism (Bartter?s Syndrome): A re-evaluation of the pathophysiology. Medicine 47: 107-131, (1968).

55. Newton MA, Laragh JH: Effect of corticotropin on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. J. Clin. Endocrinol. Metab. 28: l006-l0l3, l968.

56. Newton M.A, Laragh JH: Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects in essential hypertension and in primary aldosteronism. J. Clin. Endocrinol. Metab. 28: l0l4-l022, l968.

57. Newton MA, Sealey JE, Ledingham JGG, Laragh JH: High blood pressure and oral contraceptives. Am J Obstet Gynecol 101: 1037 1045, 1968.

58. Gocke DJ, Sherwood LM, Oppenhoff I, Gerten J, Laragh JH: Measurement of plasma angiotensin II and correlation with renin activity. J. Clin. Endocrinol. Metab. 28:1675-1678, 1968.

59. Bull MB, Laragh JH. Amiloride. A potassium sparing natriuretic agent. Circulation 37: 45-53, 1968.

60. Sealey JE, Kirshman JD, Laragh JH. Natriuretic activity in plasma and urine of salt loaded man and sheep. J Clin. Invest 48: 2210 2224, 1969.

61. Goodwin FJ, Knowlton AI, Laragh JH: Absence of renin suppression by deoxycorticosterone acetate in rats. Am. J. Physiol. 216: 2210-2224, 1969.

62. Newton MA, Laragh JH: Manipulation by corticotropin and cortisol of aldosterone secretion in primary aldosteronism. Arch. Intern. Med. 123: 147-151, 1969.

63. Baer L, Goodwin FJ, Laragh JH: Diazoxide-induced renin release in man: Dissociation from plasma and extracellular fluid volume changes. J. Clin. Endocrinol. Metab. 29: 1107-1109, 1969.

64. Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH: Pseudo-primary aldosteronism: An entity distinct from true primary aldosteronism. Circ. Res. 26 & 27: Suppl I: 203-220, 1970.

65. Bull MB, Hillman RS, Cannon PJ, Laragh JH: Renin and aldosterone secretion in man as influenced by changes in electrolyte balance and blood volume. Circ. Res. 27: 953-960, l970.

66. Krakoff LR, Goodwin FJ, Baer L, Torres M, Laragh JH: The role of renin in the exaggerated natriuresis of hypertension. Circulation 42: 335-345, l970.

67. Goodwin FJ, Kirshman JD, Sealey JE, Laragh JH: Influence of the pituitary gland on sodium conservation, plasma renin and renin substrate concentrations in the rat. Endocrinology 86: 824 834,1970.

68. Sealey JE, Clark I, Bull MB, Laragh JH: Potassium balance and the control of renin secretion. J. Clin. Invest. 49: 2ll9-2l27, l970.

69. Brunner HR, Baer L, Sealey JE, Ledingham JGG, Laragh JH: The influence of potassium administration and potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest 49: 2128 2138,1970.

70. Stoerk HC, Laragh JH, Aceto RM, Budzilovich T: Edema and ascites following the ligation of both ureters in rats. Am. J. Pathol. 58: 51-67, 1970.

71. Goodwin FJ, Ledingham JGG, Laragh JH: The effects of prolonged administration of vasopressin and oxytocin on renin aldosterone and sodium balance in normal man. Clin. Sci. 39: 641-651, 1970.

72. Sealey JE, Laragh JH: Further studies of a natriuretic substance occurring in human urine and plasma. Circ Res 28 & 29 (Suppl II): 32 43,1971.

73. Brunner HR, Kirshman JD, Sealey JE, Laragh JH: Hypertension of renal origin: evidence for two different mechanisms. Science 174: 1344 1346, 1971.

74. Laragh JH: The pill, hypertension and toxemias of pregnancy. Am. J. Obstet. Gynecol. 109: 210-213, 1971.

75. Laragh JH: Biochemical profiling and the natural history of hypertensive diseases: Low-renin essential hypertension, a benign condition. Circ. 44: 971-974, 1971. (Editorial).

76. Brunner HR, Chang P, Wallach R, Sealey JE, Laragh JH: Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin. Invest 51: 58 67, 1972.

77. Laragh JH, Baer L, Brunner HR, B?hler FR, Sealey JE, Vaughan Jr, ED: Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am. J. Med. 52: 633 652, 1972.

78. Sealey JE, B?hler FR, Laragh JH, Manning EL, Brunner HR: Aldosterone excretion: physiologic variations in man measured by radioimmunoassay or double isotope dilution. Circ. Res. 31: 367 378, 1972.

79. Laragh JH, Sealey JE, Brunner HR: The control of aldosterone secretion in normal and hypertensive man: abnormal renin aldosterone patterns in low renin hypertension. Am. J. Med. 53: 649 663, (1972.

80. Sealey JE, Gerten-Banes J, Laragh JH: The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int. l: 240-253, l972.

81. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, B?hler FR: Essential hypertension: Renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286: 44l-449, l972.

82. B?hler FR, Laragh JH, Baer L, Vaughan Jr ED, Brunner HR: Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N. Engl. J. Med. 287: l209-l2l4, l972.

83. Laragh, JH: Oral contraceptive hypertension. Postgrad. Med. 52: 99-105, 1972.

84. Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: The use of renin and aldosterone profiles. Am. J. Med. 55: 26l-274, l973.

85. Gavras H, Brunner HR, Vaughan Jr ED, Laragh JH: Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science l80: l369-l372, l973.

86. Vaughan Jr E.D, Laragh JH, Gavras I, B?hler FB, Gavras H, Brunner HR, Baer L: Volume factor in low and normal renin essential hypertension: treatment with either spironolactone or chlorthalidone. Am. J. Cardiol. 32: 523-532, 1973.

87. B?hler FR, Laragh JH, Vaughan Jr ED, Brunner HR, Gavras H, Baer L: Antihypertensive action of propranolol: Specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am. J. Cardiol. 32: 511-522, 1973.

88. Sealey JE, B?hler FR, Laragh JH, Vaughan Jr ED: The physiology of renin secretion in essential hypertension: Estimation of renin secretion rate and renal plasma flow from peripheral and renal vein renin levels. Am. J. Med. 55: 39l-40l, l973.

89. Vaughan Jr ED, B?hler FR, Laragh JH, Sealey JE, Baer L, Bard RH: Renovascular hypertension: Renin measurements to indicate hypersecretion, and contralateral suppression, estimate renal plasma flow and score for surgical curability. Am. J. Med. 55: 402-4l4, l973.

90. B?hler FR, Laragh JH, Sealey JE, Brunner HR: Plasma aldosterone-renin interrelationships in various forms of essential hypertension: Studies using a rapid assay of plasma aldosterone. Am. J. Cardiol. 32: 554-561, 1973.

91. Laragh JH, Sealey JE, Brunner HR: Low renin hypertension. (Letter) N. Engl. J Med. 288: 1078, 1973.

92. Brunner HR, Sealey JE, Laragh JH: Renin subgroups in essential hypertension: further analysis of their pathophysiologic and epidemiologic characteristics. Circ. Res. 32 & 33 (Suppl I): 99 109, 1973.

93. B?hler FR, Laragh JH, Sealey JE, Brunner HR: Plasma aldosterone renin interrelationships in various forms of essential hypertension: studies using a rapid assay of plasma aldosterone. Am J Cardiol. 32: 554 561, 1973.

94. Brunner HR, Sealey JE, Laragh JH: Renin as a risk factor in essential hypertension: more evidence. Am J Med. 55: 295 320,1973.

95. Laragh JH: Potassium, angiotensin and the dual control of aldosterone secretion. N. Engl. J. Med. 289: 745-746, 1973.

96. Sealey JE, Laragh JH: Urinary aldosterone: radioimmunoassay technique, operating protocol. Council for Interdisciplinary Communication in Medicine, Ltd., New York, N.Y. 1973.

97. Sealey JE, Laragh JH: Human plasma renin: radioimmunoassay technique, operating protocol. Council for Interdisciplinary Communication in Medicine, Ltd., New York, N.Y. 1973.

98. Wotman S, Baer L, Mandel I D, Laragh JH: Salivary electrolytes, renin and aldosterone during sodium loading and depletion. J. Appl. Physiol. 35: 322-324, 1973.

99. Buhler FR, Laragh JH: Mechanism of beta blockade hypotension. Letter to the Editor, N. Engl. J. Med. 288:689-690, 1973.

100. Vaughan Jr ED, Gavras H, Laragh JH, Koss MN. Vascular permeability factor: Dissociation from the angiotensin II induced pressor and drinking responses. Nature 242: 334-336, 1973.

101. Sealey JE, Laragh JH: Proposed cybernetic system for sodium and potassium homeostasis: Coordination of aldosterone with changes in intrarenal physical factors. Kidney International 6: 281 290, 1974.
102. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA: An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl. J Med. 291: 817 821, 1974.

103. Brunner HR, Gavras H, Laragh JH, Keenan R: Hypertension in man. Exposure of the renin and sodium components using angiotensin II blockade. Circ. Res. 34: Suppl. I: 35-43, l974.

104. Laragh JH: Esoteric role of insulin in aldosterone secretion. Letter to the Editor, N. Engl. J. Med. 290: 109, 1974.

105. Laragh JH: Potassium, aldosterone and renin inter-relations. Letter to the Editor, N. Engl. J. Med. 290: 408, 1974.

106. Vaughan Jr ED, Buhler FR, Laragh JH: Normal renin secretion in hypertensive patients with primarily unilateral chronic hydronephrosis. J. Urol. 112: 153-156, 1974.

107. Sealey JE, Laragh JH: "Prorenin" in human plasma? Methodological and physiological implications. Circ. Res. 36 & 37: Suppl I: l0-l6, l975.

108. Gavras H, Brunner HR, Thurston H, Laragh JH: Reciprocation of renin dependency with sodium volume dependency in renal hypertension. Science l88: l3l6-l3l7, l975.

109. Gavras H, Brunner HR, Laragh JH, Vaughan Jr ED, Koss M, Cote LJ, Gavras I: Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Circ. Res. 36: 300-309, 1975.

110. Laragh JH, Sealey JE, B?hler FR, Vaughan Jr ED, Brunner HR, Gavras H, Baer L: The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am J Med. 58: 4 13, 1975.

111. Blood DK, Schmidt DH, Mallis G, Sealey JE, Laragh JH: The control of renin release during exercise. Bulletin of the New York Academy of Medicine 51: 311, 1975.

112. Sealey JE, Laragh JH: Radioimmunoassay of plasma renin activity. Seminars in Nuclear Medicine 5: 189 202,1975.

113. Vaughan Jr ED, B?hler FR, Laragh JH, Sealey JE, Gavras H, Baer L: Hypertension and unilateral parenchymal renal disease: evidence for abnormal vasoconstriction volume interaction. J. Am. Med. Assoc. 233: 1177 1183,1975.

114. Thurston H, Laragh JH: Prior receptor occupancy as a determinant of the pressor activity of infused angiotensin II in the rat. Circ. Res. 36: 113-117, 1975.

115. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH: Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med. 60: 825 836, 1976.

116. White RP, Sealey JE, Reidenberg M, Stenzel KH, Sullivan JF, David DS, Laragh JH, Rubin AL: Mechanisms of blood pressure control in anephrics: plasma renin and dopamine b hydroxylase activity. Trans. Am Soc. Artif. Intern Organs 21: 420 424, 1976.

117. Edwards KDG, Herz R, Sealey JE, Bradley SE: Lowering of blood pressure, plasma renin substrate, cholesterol and triglyceride by portocaval anastomosis in rats fed on a 60% sucrose 5% lard diet. Clin. Sci. Mol. Med. 51: 1s 3s, 1976.

118. Sealey JE, Moon C, Laragh JH, Alderman M: Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects. Am J Med. 6l: 731 738, 1976.

119. Case DB, Wallace JM, Keim JH, Weber MA, Drayer JIM, White RP, Sealey JE, Laragh JH: Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med. 61: 790 796,1976.

120. Weber MA, Case DB, Baer L, Sealey JE, Drayer JIM, Lopez Ovejero JA, Laragh JH: Renin and aldosterone suppression in the antihypertensive action of clonidine. Am J Cardiol. 38: 825 830, 1976

121. Keim HJ, Drayer JIM, Case DB, Lopez-Ovejero JA, Wallace JM, Laragh JH: A role for renin in rebound hypertension and encephalopathy after infusion of Sar1-ala8-angiotensin II. N. Engl. J. Med. 295: 1175-1177, 1976.

122. Drayer JIM, Keim HJ, Weber MA, Case DB, Laragh JH: Unexpected pressor responses to propranolol in essential hypertension. Am. J. Med. 60: 897-903, 1976.

123. Laragh JH: Modern system for testing high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am. J. Med. 61: 797-810, 1976.

124. Laragh, JH: Antihypertensive drugs and the renin system. In, New Antihypertensive Drugs, pp 167-178, eds. A. Scriabine and S.C Sweet, Spectrum Publications, New York, 1976.

125. Wallace JM, Case DB, Laragh JH, Sealey JE, Keim HJ, Drayer JIM: The immediate pressor response to saralasin: a measure of the degree of angiotensin II vascular receptor vacancy. Trans. Assoc. Am. Physicians, 90: 300-3l2, l977.

126. Laragh JH, Case DB, Wallace JM, Keim H: Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade. Fed. Proc. 36: l78l-l787, l977.

127. Weber MA, Lopex-Ovejero JA, DrayerJIM, Case DB, Laragh JH: Renin reactivity as a determinant of responsiveness to antihypertensive treatment. Arch. Intern. Med. 137: 284-289, 1977.

128. Weber MA, Drayer JIM, Rev A, Laragh JH: Disparate patterns of aldosterone response during diuretic treatment of hypertension. Ann. Int. Med. 87: 558-563, 1977.

129. Gavras H, Gavras I, Cannon PJ, Brunner HR, Laragh JH: Is elevated plasma renin activity of prognostic significance in progressive systemic sclerosis? Archives of Intern. Med. 137: 1554-1558, 1977.

130. Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH: Possible role of renin in hypertension as suggested by renin sodium profiling and inhibition of converting enzyme. N Engl. J Med. 296: 641 646, 1977.

131. Sealey JE, Moon C, Laragh JH, Atlas SA: Plasma prorenin in normal, hypertensive and anephric subjects and its effect on renin measurements. Circ. Res. 40 (Suppl I): 41 45, 1977.

132. Sealey JE, White RP, Laragh JH, Rubin AL: Plasma prorenin and renin in anephric patients. Circ. Res. 4l (Suppl II): 17 20, 1977.

133. Atlas SA, Sealey JE, Laragh JH, Moon C: Plasma renin and "prorenin" in essential hypertension during sodium depletion beta blockade and reduced arterial pressure. Lancet II, 785 789, 1977.

134. Sealey JE, Laragh JH: How to do a plasma renin assay. Cardiovascular Medicine 2: 1079 1092, 1977.

135. Roberts AJ, Niarchos AP, Subramanian VA, Abel RM, Herman SD, Sealey JE, Case DB, White RP, Johnson GA, Laragh JH, Gay WA: Systemic hypertension associated with coronary artery bypass surgery. J Thoracic Cardio. Surg. 74: 846 859, 1977.

136. Drayer JIM, Weber WA, Atlas SA, Laragh JH; Phentolamine testing for alpha adrenergic participation in hypertensive patients: independence from renin profiles. Clin. Pharmacol. Ther. 22: 286-292, 1977.

137. Sealey JE, White RP, Laragh JH, Case DB, Rubin AL: Studies of plasma aldosterone in anephric people: evidence for fundamental role of the renin system in maintaining aldosterone secretion. J Clin. Endocrinol. Metab. 47: 52 60, 1978.

138. Atlas S.A, J.E Sealey, J.H Laragh. Protease as endogenous activator of inactive renin. (Letter) Lancet I: 555, 1978.

139. Atlas SA, Sealey JE, Laragh JH: "Acid" and "cryo"activated inactive plasma renin: similarity of changes during_b blockade and evidence that neutral protease(s) participate in both activation procedures. Circ. Res. 43 (Suppl I): 128 133, 1978.

140. Atlas SA, Laragh JH, Sealey JE: Activation of inactive plasma renin: evidence that both cryo and acidactivation work by liberating a neutral serine protease from endogenous inhibitors. Clin. Sci. Mol. Med. 55: 135s 138s, 1978.

141. Sealey JE, Atlas SA, Laragh JH, Oza NB, Ryan JW: Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature 275: 144 145. 1978.

142. Sealey JE, Atlas SA, Laragh JH: Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis. Am. J. Med. 65: 994 1000,1978.

143. Lopez Ovejero JA, Weber MA, Drayer JIM, Sealey JE, Laragh JH: Effects of indomethacin alone and during diuretic or B adrenoreceptor blockade therapy on blood pressure and the renin system in essential hypertension. Clin. Sci. Mol. Med. 55: 203s 205s, 1978.

144. Davies R, Morganti A, Morselli PL, Pickering TG, Bianchetti G, Romankiewicz J, Laragh JH: Beta-blockade and blood levels after low-dose oral propranolol: The hepatic "First-Pass" threshold revisited. The Lancet 25: 407-410, 1978.

145. Laragh JH: The renin system in high blood pressure, from disbelief to reality: converting-enzyme blockade for analysis and treatment. Prog. in Cardiovasc. Dis. 2l: l59-l66, 1978.

146. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, Mckinstry DN: Clinical experience with blockade of the renin angiotensin aldosterone system by captopril (SQ l4225) in hypertensive patients. Prog. Cardiovasc. Dis. 21: 195 206, 1978.

147. Case DB, Cassarella WJ, Laragh JH, Fowler DL, Cannon PJ: Renal cortical blood flow and angiography in low-and normal-renin essential hypertension. Kidney Intl. 13:236-244, 1978.

148. Drayer JIM, Weber MA, Longworth DL, Laragh JH: The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol. Am.J.Med. 64: 187-192, 1978.

149. Weber MA, Drayer JIM, Laragh JH: The effects of clonisine lonidine and propranolol, separately and in combination, on blood pressure and plasma renin activity in essential hypertension. J.Clin.Pharmacol. 18: 233-240, 1978.

150. Davies R, Pickering TG, Morganti A, Bianchetti G, Morselli P, Romankiewicz J, Laragh JH: Low dose oral propranolol (Letter) Lancet I: 827-828, 1978.

151. Morganti A, Lopez-Ovejero JA, Pickering TG, Laragh JH: Role of the sympathetic nervous system in mediating the renin response to head up tilt. Their possible synergism in defending blood pressure against postural changes during sodium deprivation. Am. J. Cardiol. 43: 600-604, l979.

152. Niarchos AP, Roberts AJ, Case DB, Gay Jr WA, Laragh JH: Hemodynamic characteristics of hypertension after coronary bypass surgery and effects of the converting enzyme inhibitor. Am. J. Cardiol. 43: 423, 1979.

153. Laragh JH, Letcher RL, Pickering TG: Renin profiling for modern diagnosis and treatment of hypertension. JAMA 24l: l5l-l56, l979.

154. Lopez-Ovejero JA, Saal SD, D?Angelo WA, Cheigh JS, Stanzel H, Laragh JH: Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N. Engl. J. Med. 300: 1417-1418, 1979.

155. Niarchos AP, Roberts AJ, Laragh JH: Effects of the converting enzyme inhibitor SQ 2088l on the pulmonary circulation in man. Am. J. Med. 67: 785-789, l979.

156. Wallace JM, Case DB, Laragh JH, Keim HJ, Drayer JIM, Sealey JE: The immediate pressor response to saralasin in man: a test of angiotensin II receptor vacancy. Circ. Res. 44: 38-44, l979.

157. Case DB, Laragh JH: Reactive hyperreninemia in renovascular hypertension following angiotensin blockade with either saralasin or converting enzyme inhibitor. Ann. Int. Med. 91: 153-160, 1979.

158. Niarchos AP, Pickering TG, Case DB, Sullivan PA, Laragh JH: Role of the renin-angiotensin system in blood pressure regulation: The cardiovascular effects of converting enzyme inhibition in normal man. Circ. Res. 45: 829-837, l979.

159. Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP: Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc. Natl. Acad. Sci., 76: 59l4-59l8, l979.

160. Meltzer JI, Keim HJ, Laragh JH, Sealey JE, Jan KM, Chien S: Nephrotic Syndrome: Vasoconstrictive and hypervolemic forms suggested by renin profiling. Ann. Int. Med. 9l: 688-696, l979.

161. Pickering TG, Raine AEG, Levitt M, Morganti A, Niarchos AP, Laragh JH: Immediate and delayed hypotensive effects of propranolol at rest and during exercise. Trans. Assoc. Am. Physicians, Pub. by William J. Dornan, Inc., Collingdale, Pa., 92: 277-285, l979.

162. Davies R, Pickering TG, Morganti A, Wilson M, Laragh JH: Blockade of cardiac and renal beta-receptors by low dose propranolol in normal subjects: clues to its hypertensive effect. Brit. Heart. J. 41: 331-333, 1979.

163. Morganti A, Sealey JE, Lopez Ovejero JA, Pickering TG, Laragh JH: The substitutive role of ACTH in supporting aldosterone response to headup tilt during acute renin suppression in patients with essential hypertension. Hypertension 1: 130 135, 1979.

164. Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH: Contrasting effects of acute beta blockade with propranolol on plasma catecholamines and renin in essential hypertension: a possible basis for the delayed antihypertensive response. Am. Heart J. 98: 490-494, 1979.

165. Sealey JE, Atlas SA, Laragh JH, Oza NB, Ryan JW: Activation of a prorenin like substance in human plasma by trypsin and by urinary kallikrein. Hypertension 1: 179 189, 1979.

166. Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN: Interruption of the renin angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1: 274 280,1979

167. Sealey JE, Atlas SA, Laragh JH: Glandular kallikrein. N Engl. J Med. (Letter) 301: 729 730, 1979.

168. Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP: Plasmin can activate plasma prorenin but is not required for the alkaline phase of acid activation. Clin. Sci. 57: 97s 99s, 1979.

169. Wilson M, Morganti A, Zervoudakis I, Letcher RL, Von Oeyon P, Papera S, Sealey JE, Laragh JH: Blood pressure, the renin aldosterone system and sex steroids throughout normal pregnancy. Am J Med. 68: 97 104,1980.

170. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE: Use of first dose response of plasma renin activity to predict long term effect of captopril: identification of its triphasic pattern of blood pressure response. J Cardiovasc Pharmacol 2: 339 346,1980.

171. Gallagher JR, Laragh JH, Atlas SA, Sealey JE: Effect of trypsin or acid treatment on dog plasma renin activity measurements. Endocrinology 107: 147 154,1980

172. Atlas SA, Laragh JH, Sealey JE, Hesson TE: An inactive, prorenin like substance in human kidney and plasma. Clin. Sci. 59: 29s 33s, 1980.

173. Laragh JH, Case DB, Atlas SA, Sealey JE: Captopril compared with other anti renin system agents in hypertensive patients. Its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 2: 586 593,1980.

174. Longworth DL, Drayer JIM, Weaber MA, Laragh JH: Divergent blood pressure responses during short-term sodium restriction in hypertension. Clin. Pharm. Therapeut. 27: 544-546, 1980.

175. Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH: Endocrine and cardiovascular influences of converting enzyme inhibition with SQ l4225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion. J. Clin. Endocrinol. Metab. 50: 748-754, 1980.

176. Morganti A, Pickering TG, Lopez-Ovejero JA, Laragh JH: High and low renin subgroups of essential hypertension: differences and similarities in their renin and sympathetic responses to neural an nonneural stimuli. Am.J.Cardiol. 46: 306-312, 1980.

177. Niarchos AP, Pickering TG, Wallace JM, Case DB, Laragh JH: Hemodynamic effects of converting enzyme inhibitor teprotide in normal-and high-renin hypertension. Clin. Pharm. Ther. 28: 592-601, 1980.

178. Case DB, Atlas SA, Sullivan PA, Laragh JH: Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril. Circulation 64: 765-77l, 198l.

179. Atlas SA, Sealey JE, Dharmgrongartama B, Hesson TE, Laragh JH: Detection and isolation of inactive, large molecular weight renin in human kidney and plasma. Hypertension Supplement 3: I30-I40, l98l.

180. Drayer JIM, Weber MA, Sealey JE, Laragh JH: Low and high renin essential hypertension: A comparison of clinical and biochemical characteristics. Am. J. Med. Sci. 281:135-142, 1981.

181. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH: Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med. 70: 1195 1202, 1981.

182. Blumberg AL, Sealey JE, Atlas SA, Laragh JH, Dharmgrongartama B, Kaplan AP: Contact activation of human plasma prorenin in vitro. J Lab Clin. Med. 97: 771 778, 1981.

183. Sealey JE, Overlack A, Laragh JH, Stumpe KO, Atlas SA: Effect of captopril and aprotinin on inactive renin. J Clin. Endocrinol. Metab. 53: 626 630,1981.

184. Atlas SA, Case DB, Sealey JE, Laragh JH: Relationship between plasma renin and cortisol in hypertensive patients. Clin. Sci. 61: 265s 268s, 1981.

185. Laragh, JH: The renin-angiotensin-aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyze different forms of hypertension. In: Frontiers in Hypertension Research. J.H. Laragh, F.R. Buhler, D.W. Seldin, (Eds). Springer-Verlag, New York, 183-194, 1981.

186. Laragh, JH: Hypertension, vasoconstriction, and the causation of cardiovascular injury: The renin-sodium profile as an indicator of risk. In: Frontiers in Hypertension Research, J.H. Laragh, F.R. Buhler, D.W. Seldin, (Eds)., Springer-Verlag, New York, 383-385, 1981.

187. Cody RJ, Franklin KW, Kluger J, Laragh JH: Sympathetic responsiveness and plasma norepiperphrine during therapy of chronic congestive heart failure with captopril. Am.J. Med. 72: 791-797, 1982.

188. Preibisz JJ, Sealey JE, Aceto RM, Laragh JH: Plasma renin activity measurements: An update. Cardio Rev & Rep 5: 787 804,1982.

189. Atlas SA, Sealey JE, Hesson TE, Kaplan AP, Menard J, Corvol P, Laragh JH: Biochemical similarity of partially purified inactive renins from human plasma and kidney. Hypertension 4 (Suppl II): 86 95, 1982.

190. Bradley SE, Coelho JB, Sealey JE, Edwards KDG, Stephan F: Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin angiotensin system in hypothyroid rats. Life Sciences 30: 633 639,1982.

191. Atlas SA, Hesson TE, Sealey JE, Laragh JH: Reversible acid activation of inactive renins: Evidence favoring a unimolecular reaction. Clin. Sci. 63: 167s 170s, 1982.

192. Sealey JE, Wilson M, Morganti A, Zervoidakis I, Laragh JH: Changes in active and inactive renin throughout normal pregnancy. Clin. Exp. Hypertens. A4: 2373 2384,1982.

193. Atlas SA, Sealey JE, Hesson TE, Laragh JH: Apparent molecular size difference between plasma and renal inactive renins. Clin. Exp. Hypertens. A4: 2039 2048, 1982.

194. Muirhead EE, Rightsel WA, Pitcock JA, Inagami T, Okamura T, Takii V, Goodfriend TL, Sealey JE, Brooks B, Brown P: Cultured juxtaglomerular cells cause hypertension by secreting angiotensin. Trans. Assoc. Am Physicians 95: 110 119, 1982.

195. Whitman III HH, Case DB, Laragh JH, Christian CL, Botstein G, Maricq H, Leroy EC: Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arth. & Rheum. 25: 241-248, 1982.

196. Pickering TG, Harshfield GA, Kleinert HD, Blank S, Laragh JH: Blood pressure during normal daily activities, sleep and exercise, comparison of values in normal and hypertensive subjects. JAMA 247: 992-996, l982.

197. Case DB, Atlas SA, Marion RM, Laragh JH: Long-term efficacy of captopril in renovascular and essential hypertension. Am.J. Cardiol. 49: 1440-1446, 1982.

198. Kluger J, Cody RJ, Laragh JH: The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors. Am. J. Cardiol. 49: 1667-1674, 1982.

199. Cody RJ, Franklin KW, Kluger J, Laragh JH: Mechanisms governing the postural response and baroreceptor abnormalities in chronic congestive heart failure: effects of acute and long-term converting enzyme inhibition. Circulation. 66:135-142, 1982.

200. Pickering TG, Case DB, Sullivan PA, Laragh JH: Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. Am. J. Cardiol. 49: 1566-1568, 1982.

201. Laragh JH, Sealey JE, Niarchos AP, Pickering TG: The vasoconstriction-volume spectrum in normotension and in the pathogenesis of hypertension. Federation Proceedings 4l: 24l5-2423, l982.

202. Devereux RB, Pickering TG, Laragh JH: Left-ventricular mass in hypertension. Lancet (May) 1021-1022, 1982.

203. Devereux RB, Savage DD, Drayer JIM, Laragh JH: Left ventricular hypertrophy and function in high, normal, and low-renin forms of essential hypertension. Hypertens. 4:524-531, 1982.

204. Niarchos AP, Pickering TG, Laragh JH: Cardiovascular responses to isometric exercise and standing in normotensive subjects during converting enzyme inhibition with teprotide. Hypertens. 4:538-544, 1982.

205. Cody RJ, Franklin KW, Laragh JH: Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am. Heart J. 103: 480-484, 1982.

206. Drayer JIM, Weber MA, Laragh JH, Sealey JE: Renin subgroups in essential hypertension. Clinical and Experimental Hypertension - Theory and Practice A4 (9&10): 1817-1834, 1982.

207. Niarchos AP, Whitman HH, Goldstein JE, Laragh JH: Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am. Heart J. 104:834-838, 1982.

208. Cody RJ, Laragh JH, Atlas SA, Case DB: Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure. J. Hypertension 1: (suppl I): 77-84, 1983.

209. Laragh JH, Pecker MS: Dietary sodium and essential hypertension: Some myths, hopes, and truths. Ann. Intern. Med. 98:735-743, l983.

210. Sos TA, Pickering TG, Sniderman K, Saddenki S, Case DB, Silane MF, Vaughan Jr ED, Laragh JH: Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N. Engl. J. Med. 309:274-279, l983.

211. Sealey JE, Atlas SA, Laragh JH: Prorenin in plasma and kidney. Federation Proceedings 42: 268l-2689, l983.

212. Cody R.J, Laragh JH, Case DB, Atlas SA: Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension (Suppl III) 5: III-36-42, 1983.

213. Sos TA, Vaughan ED, Pickering TG, Case DB, Sniderman KW, Sealey JE, Laragh JH: Diagnosis of renovascular hypertension and evaluation of "surgical" curability. Urol Radiol 3: 199 203,1983.

214. Kleinert HD, Leslie BR, Laragh JH, Vaughan ED, Sealey JE: Comparable effect of isotonic infusions on blood pressure in the anephric rat. Hypertension 5:421 426, 1983.

215. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5 (Suppl I): 129 138,1983.

216. Covit AB, Shaer GL, Sealey JE, Laragh JH, Cody RJ: Suppression of the renin angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med. 75:445 447, 1983.

217. Resnick LM, Laragh JH, Sealey JE, Alderman MH: Divalent cautions in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl. J Med. 309: 888 891, 1983.

218. Nicholson JP, Vaughan Jr ED, Pickering TG, Resnick LM, Artusio J, Kleinert HD, Lopez-Ovejero JA, Laragh JH: Pheochromocytoma and prazosin. Ann. Intern. Med. 99:477-479, 1983.

219. Cody RJ, Covit AB, Schaer GL, Laragh JH: Estimation of angiotensin II receptor activity in chronic congestive heart failure. Am. Heart J. 108:81-89, 1984.

220. Atlas SA, Hesson TE, Sealey JE, Dharmgrongartama B, Laragh JH: Characterization of inactive renin ("prorenin") from renin secreting tumors of non renal origin: Similarity to inactive renin from kidney and normal plasma. J Clin. Invest 73: 437 447,1984.

221. Pickering TG, Sos TA, Vaughan ED, Case DB, Sealey JE, Harshfield GA, Laragh JH: Predictive value and changes of renin secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. Am J Med. 76: 398 404, 1984.

222. Camargo MJF, Kleinert HD, Atlas SA, Sealey JE, Laragh JH, Maack T: Ca dependent hemodynamic and natriuretic effects of atrial extract in isolated rat kidney. Am J Physiol 246: F447 F456, 1984.

223. Kleinert HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh JH: Atrial natriuretic factor inhibits angiotensin , norepinephrine , and potassium induced vascular contractility. Hypertension 6 (Suppl I): 143 147, 1984.

224. Atlas SA, Kleinert HD, Camargo MJF, Januszewicz A, Sealey JE, Laragh JH, Schilling JW, Lewicki JA, Johnson LK, Maack T: Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature 309: 717 719, 1984.

225. Resnick LM, Muller FB, Laragh JH, Sealey JE, Alderman MH: Divalent cautions in essential hypertension. (Letter) N Engl. J Med. 311: 605, 1984.

226. Brown JJ, Lever AF, Robertson JIS, Semple PF, Bing RF, Heagerty AM, Swales JD, Thurston H, Ledingham JGG, Laragh JH, Hansson L, Nicholls MG, Espiner AA: Salt and Hypertension. Lancet 2: 456, 1984.

227. Devereux RB, Drayer JIM, Chien S, Pickering TG, Letcher RL, de Young JI, Sealey JE, Laragh JH: Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 54:592 595,1984.

228. Iamanaka M, Greenberg B, Johnson L, Seilhamer J, Brewer M, Freidemann T, Milller J, Atlas SA, Laragh JH, Lewicki J, Fiddes J: Cloning and sequence analysis of the cDNA for the rat atrial natriuretic factor precursor. Nature 309:7l9-722, l984.

229. Maack T, Marion DM, Camargo MJF, Kleinert HD, Laragh JHL, Vaughan Jr ED, Atlas SA: Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. Am. J. Med. 77:l05l-l068, l984.

230. Niarchos, AP, Laragh JH: Renin dependency of blood pressure in isolated systolic hypertension. Am. J. Med. 77:407-414, 1984.

231. Volpe M, Odell G, Kleinert HD, Camargo MJF, Laragh JH, Lewicki JA, Maack T, Vaughan Jr ED, Atlas SA: Antihypertensive and aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension. J. Hypertens. 2 (3): 313-315, 1984.

232. Volpe M, Odell G, Kleinert HD, M?ller F, Camargo MJF, Laragh JH, Maack T, Vaughan ED, Atlas SA: Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension 7(3): I-43-I-48, l985.

233. Resnick LM, Nicholson JP, Laragh JH: Alterations in calcium metabolism mediate dietary salt sensitivity in essential hypertension. Transactions of the Association of American Physicians, 98th Session. Vol. XCVIII, 1985 pp. 313-321.

234. Kubo SH, Cody RJ, Laragh JH, Prida XE, Atlas SA, Yuan Z, Sealey JE: Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. Amer. J. Cardiol. 55: l22-l26, (1985).

235. Sealey JE, McCord D, Taufield PA, Ales KA, Druzin ML, Atlas SA, Laragh JH: Plasma prorenin in first trimester pregnancy: relationship to changes in human chorionic gonadotropin. Am J Obstet Gynecol. 153: 514 519, 1985.

236. Sealey JE, Glorioso N, Toth A, Atlas SA, Laragh JH: Stimulation of plasma prorenin by gonadotropic hormones. (Letter) Am J Obstet Gynecol. 153:5 96, 1985.

237. Atlas SA, Christofalo P, Hesson T, Sealey JE, Fritz LC: Immunological evidence that inactive renin is prorenin. Biochem. Biophys. Res. Commun. 132:1038 1045, 1985.

238. Sealey JE, Atlas SA, Glorioso N, Manapat H, Laragh JH: Cyclical secretion of prorenin during the menstrual cycle: Synchronization with luteinizing hormone and progesterone. Proc. Nat'l. Acad. Sci. USA 82: 8705 8709, 1985.

239. Pickering TG, Sos TA, James G, Vaughan Jr ED, Sealey JE, Laragh JH: Comparison of renal vein renin activity in hypertensive patients with stenosis of one or both renal arteries. J Hypertension 3 (Suppl 3): S291 S293, 1985.

240. Niarchos AO, Resnick LM, Weinstein DL, Laragh JH: Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy. Am. J. Med. 79(4): 435-444, 1985.

241. Laragh JH: Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N. Engl. J. Med. 313: 1330-1340, 1985.

242. Atlas SA, Kleinert HD, Camargo MJF, Volpe M, Laragh JH, Lewicki JA, Maack T: Atrial natriuretic factors (Auriculin): Structure and biological effects. J. Clin. Hypertens. 2:187-197, 1985.

243. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J: Sodium and water balance in chronic congestive heart failure. J. Clin. Invest. 77: 1441-1452, 1986.

244. Cody RJ, Kubo SH, Covit AB, Mullelr FB, Lopez-Ovejero JA, Laragh JH: Exercise hemodynamics and oxygen delivery in human hypertension: Response to verapamil. Hypertens. 8:3-10, 1986.

245. Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH: The captopril test for identifying renovascular disease in hypertensive patients. Am J Med. 80: 633 644, 1986.

246. Glorioso N, Atlas SA, Laragh JH, Jewelewicz R, Sealey JE: Prorenin in high concentrations in human ovarian follicular fluid. Science 233: 1422 1424, 1986.

247. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E: Increased plasma renin and aldosterone in patients treated with cisplatin based chemotherapy for metastatic germ cell tumors. J Clin Oncol 4: 1684 1689, 1986.

248. Glorioso N, Troffa C, Atlas SA, Sealey JE: Acid activable inactive renin in cat plasma and kidney. J Hypertension 4, (Suppl 5): S6 S9, 1986.

249. Sealey JE, Glorioso N, Itskovitz J, Troffa C, Cholst I, Rosenwaks Z: Plasma prorenin during early pregnancy: ovarian secretion under gonadotropin control? J Hypertension 4, (Suppl 5): S92 S95, 1986.

250. Taufield PA, Druzin ML, Edersheim TE, Sealey JE, Laragh JH: Correlation between plasma renin activity and birthweight in hypertensive pregnancy. J Hypertension 4 (Suppl 5): S96 S9, 1986.

251. James GD, Sealey JE, Muller FB, Alderman M, Madhavan S, Laragh JH: Renin relationship to sex, race and age in a normotensive population. J Hypertension 4 (Suppl 5): S387 S389, 1986.

252. Resnick LM, Gupta RK, Sosa RE, Corbett ML, Sealey JE, Laragh JH: Effects of altered dietary calcium intake in experimental hypertension: role of intracellular free magnesium. J Hypertens 4 (Suppl 5): S182-S185, 1986.

253. Resnick LM, Sosa RE, Corbett ML, Gertner JM, Sealey JE, Laragh JH: Effects of dietary calcium on sodium volume vs. renin dependent forms of experimental hypertension. In: Transactions of the Association of American Physicians, 99th Sessions, Vol XCIX. Waverly Press, Baltimore. pp 172 179 [Trans. Assoc. Am Physicians 99: 172-179, 1986.

254. Casale PN, Devereux RB, Milner MM, Zullo G, Harshfield GA, Pickering TG, Laragh JH: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive man. Ann. Intern. Med. 105(2): 173-178, August, 1986.

255. Volpe M, Sosa RE, M?ller FB, Camargo MJF, Glorioso N, Laragh JH, Maack T, Atlas SA: Differing hemodynamic responses to atrial natriuretic factor in two models of hypertension. Am. J. Physiol. 250 (Heart Circ. Physiol. l9): H87l-H878, l986.

256. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJF, Scarborough RM, Lewicki JA: Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 78: l362-l374, l986.

257. Resnick LM, M?ller FB, Laragh JH: Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism. Ann. Intern. Med. l05: 649-654, l986.

258. Resnick LM, Nicholson JP, Laragh JH: Calcium metabolism in essential hypertension: relationship to altered renin system activity. Fed. Proc. 45: 2739-2745, l986.

259. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J: Sodium and water balance in chronic congestive heart failure. J. Clin. Invest. 77 (5): l44l-l452, l986.

260. Kleinert HD, Volpe M, Odell G, Marion D, Atlas SA, Camargo MJF, Laragh JH, Maack T: Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs. Hypertens. 8: 312-316, 1986.

261. Laragh, JH. Cody RJ, Covit AB, Atlas SA. The renin system and atrial natriuretic hormone in congestive heart failure. Acta Medica Scandinavica, Supplementum 707: 45-53, 1986.

262. Sosa RE, Volpe M, Marion D, Atlals SA, Laragh JH, Vaughan ED, Maack T: Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am. J. Physiol. 250 (Renal Fluid Electrolyte Physiol. 19): F520-F524, 1986.

263. Laragh JH: Endocrine mechanisms in congestive failure: Renin, aldosterone, and atrial natriuretic hormone. Drugs 32: (5) 1-12, 1986.

264. Sealey JE, Cholst I, Glorioso N, Troffa C, Weintraub ID, James G, Laragh JH: Sequential changes in plasma luteinizing hormonal and plasma prorenin during the menstrual cycle. J. Clin. Endocrinol. & Metabol. 63: l-5, l987.

265. Taufield PA, Ales KL, Resnick LM, Druzin ML, Gertner JM, Laragh JH: Hypocalciuria in preeclampsia. N. Engl. J. Med. 3l6 (l2): 7l5-7l8, l987.

266. Glorioso N, Troffa C, Laragh JH, Atlas SA, Marion D, Sealey JE: The cat: An animal model for studies of inactive renin. Am J Physiol 252 (Endocrinol Metab l5): E509 E518, 1987.

267. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibiszj JJ, Scheiner E; Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours. Intl. J Andrology 10: 353 357,1987.

268. Devereux RB, Pickering TG, Cody RJ, Laragh JH: Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. J. Clin. Hypertens. 3:87-103, 1987.

269. Devereux RB, Castel PN, Hammond IW, Savage DD, Alderman MH, Campo E, Alonso DR, Laragh JH: Echocardiographic detection of pressure-overload left ventricular hypertrophy. Effect of criteria and patient population. J. Clin. Hypertens. 3:66-78, 1987.

270. Nicholson JP, Resnick LM, Laragh JH: The antihypertensive effect of varapamil at extremes of dietary sodium intake. Ann. Intern. Med. 107:329-334, 1987.

271. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ: Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am.J.Cardiol. 60: (61) 1322-1328, 1987.

272. Cody R.J, Laragh JH: Editorial: The metamorphosis of angiotensin-converting-enzyme inhibitor therapy for congestive heart failure. Heart Failure 3: (3) 99-100, 1987.

273. Sealey JE, Goldstein M, Pitarresi T, Kudlak TT, Glorioso N, Fiamengo SA, Laragh JH: Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. J Clin Endocrinol Metab 66: 974 978, 1988.

274. James GD, Sealey JE, Alderman M, Ljungman S, Muller FB, Pecker MS, Laragh JH: A longitudinal study of urinary creatinine and creatinine clearance in normal subjects: race, sex and age differences. Am J Hypertension 1: 124 131, 1988.

275. Sealey JE, Lenz T, Glorioso N, Itskovitz J: High levels of circulating prorenin in pregnancy. (Letter) Am J Obstet Gynecol 158: 681 682, 1988.

276. Cody RJ, Ljungman S, Covit AB, Kubo SH, Sealey JE, Pondolfino K, Clark M, James GD, Laragh JH: Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Intl. 34: 361 367, 1988.

277. Laragh JH, Lamport B, Sealey JE, Alderman MH: Diagnosis ex juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 12: 223 226, 1988.

278. Sealey JE, Blumenfeld JB, Bell GM, Pecker MS, Sommers SC, Laragh JH: On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion. J Hypertension 6: 763 777, 1988.

279. Pickering TG, Devereux RB, James GD, Silane MF, Herman L, Sotelo JE, Sos TA, Laragh JH: Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical revascularization. Lancet. II, 55l-552, l988.

280. Pickering TG, James GD, Boddie C, Harshfield G, Blank S, Laragh JH: How common is white coat hypertension? JAMA 259: (2) 225-228, 1988.

281. Laragh JH, Resnick LM: Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Intern. 34 (Suppl 25): Sl62-Sl74, l988.

282. Nicholson JP, Resnick LM, Laragh JH: Hydrochlorothiazide is not additine to verapamil in treating essential hypertension. Arch. Intern. Med. l49: l25-2l8, l989.

283. James GD, Pickering TG Yee LS, Harshfield GA, Riva S, Laragh JH: The reproducibility of average ambulatory, home, and clinic pressures. Hypertension II:545-549, 1988.

284. Blake J, Devereux RB, Herrold EM, Jason M, Fisher J, Borer JS, Laragh JH: Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am. J. Cardiol. 62:246-252, 1988.

285. Mann SJ, Pickering TG, Alderman MH, Laragh JH: Assessment of the effects of alpha- and beta-blockade in hypertensive patients who smoke cigarettes. Am. J. Med. (suppl lB): 86, 79-8l, l989.

286. Laragh JH: Extrarenal tissue prorenin systems do exist. Are intrinsic vascular and cardiac tissue renin fact or fancy? Am. J. Hypertens. 2: 262-265, 1989.

287. Bell GM, Bernstein RK, Laragh JH, Atlas SA, James GD, Pecker MS, Sealey JE: Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clinical Science 77: 177-183, 1989.

288. Bond AL, Taufield PA, Druzin ML, Atlas SA, Sealey JE, Laragh JH: Atrial natriuretic factor in normal and hypertensive pregnancy. Am J Obstet. Gynecol. 160: 1112-1116, 1989.

289. Lenz T, Sealey JE, August P, James GD, Laragh JH: Tissue levels of active and total renin, angiotensinogen, hCG, estradiol and progesterone in human placentas from different methods of delivery. J Clin. Endocrinol. Metab. 69: 31-37, 1989.

290. August P, Cody RJ, Sealey JE, Laragh JH: Hemodynamic responses to converting enzyme inhibition in patients with renal disease. Am J Hypertension 2: 599-603,1989.

291. Rubattu S, Marion DN, Peterson M, Sealey JE: Dexamethasone inhabitable stimulation of plasma prorenin by ketamine in cats. Endocrinology 125: 1533-1539,1989.

292. Nicholson JP, Resnick LM, Laragh JH: Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Archives of Intern. Med. 149:125-128,1989.

293. Laragh JH: Issues, goals, and guidelines in selecting first-line drug therapy for hypertension. Hypertension 13 (Suppl 1): 103-112, 1989.

294. Ganau A. Devereux RB, Atlas SA, Pecker M, Roman M, Vargiu P, Cody RJ, Laragh JH: Plasma atrial natriuretic factor in essential hypertension: Relation to cardiac size, function and systemic hemodynamics. J. Am. Coll. Cardiol. 14: 3, 715-724, 1989.

295. Laragh, JH: Special Award: Presentation of the Harvey Award to Arthur C. Guyton. Am. J. Hypertens. 2:573-574, 1989.

296. Volpe M, Camargo MJF, Muller FB, Campbell Jr WG, Sealey JE, Pecker MS, Sosa RE, Laragh JH: Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension 15: 318-326, 1990.

297. Lenz T, Sealey JE, Lappe RW, Carilli C, Oshiro GT, Baxter JD, Laragh JH: Infusion of recombinant human prorenin into rhesus monkeys: effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone. Am J Hypertens 3: 257-26,1990.

298. Volpe M, Atlas SA, Sosa ER, Marion DE, Muller FB, Sealey JE, Laragh JH: Angiotensin II-induced atrial natriuretic factor release in dogs is not related to hemodynamic responses. Circ. Res. 67: 774-779, 1990.

299. Bell GM, Atlas SA, Pecker M, Sealey JE, James GD, Laragh JH: Diurnal and postural variations in plasma atrial natriuretic factor, plasma guanosine 3':5'-cyclic monophosphate and sodium excretion. Clin. Sci. 79: 371-376, 1990.

300. August P, Lenz T, Ales KL, Druzin ML, Edersheim TG, Hutson JM, Muller FB, Laragh JH, Sealey JE: Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: Deviations related to the development of superimposed preeclampsia. Am J Obstet. Gynecol. 163: 1612-1621, 1990.

301. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall P, Santucci S, Spitzer M, Laragh JH: Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circ. 81:25-36, 1990.

302. DeSimone G, Devereux RB, Chien S, Alderman M, Atlas SA, Laragh JH: Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in normal adults. Circ. 81: 107-117, 1990.

303. Ljungman S, Laragh JH, Cody RJ: The role of the kidney in congestive heart failure, relationship of cardiac index to kidney function. Drugs 39 (4) 10-21, 1990.

304. DeSimone G, Wallerson D, Volpe M, Devereux RB, Laragh JH: Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Am. J. Hypertens. 3: 688-696, 1990.

305. Pickering TG, Laragh JH: Renovascular Hypertension. In: The Kidney 4th Ed. Eds B.M. Brenner and F.C. Rector, Jr. W.B. Saunders Co. Philadelphia, 1940-1967, 1991.

306. Koren M.J, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals 114 (5): 345-352, 1991.

307. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324: 1098-1104, 1991.

308. James GD, Pickering TG, Laragh JH: Ambulatory blood pressure variation is related to plasma renin activity in borderline hypertensive men. Am. J. Hypertens. 4:525-528, 1991.

309. Lenz T, Sealey JE, Maack T, James GD, Heinrikson RL, Marion D, Laragh JH: Half-life, hemodynamic, renal and hormonal effects of prorenin in cynomologus monkeys. Am. J. Physiol. 260 (Regulatory Integrative Comp. Physiol. 29): R804-R810, 1991.

310. Sealey JE, Von Lutterotti N, Rubattu S, Campbell Jr WG, Gahnem F, Halimi J-M, Laragh JH: The greater renin system: Its prorenin - directed vasodilator limb. Relevance to diabetes mellitus, pregnancy and hypertension. Am. J. Hypertens. 4(12): Part I, 972-977, 1991.

311. Nicholson PJ, Resnick LM, Cigarroa J, Marion D, Vaughan Jr ED, Laragh JH: The pressor effect of sodium-volume expansion is calcium mediated. Am. J. Hypertens. 4:11, 904-908, 1991.

312. Cody RJ, Kubo SH, Laragh JH, Atlas SA, Shaknovich A, Ryman K: Exercise-induced secretion of atrial natriuretic factor and its relation to hemodynamic and sympathetic stimulation in untreated essential hypertension. Am. J. Cardiol. 68: 918-924, 1991.

313. von Lutterotti N, Gulmi F, Marion D, Vaughan Jr ED, Laragh JH, Sealey JE: Increased plasma prorenin but not renin after bilateral ureteral ligation in dogs. Kidney Intl. 39:901-908, 1991.

314. Lenz TY, James GD, Laragh JH, Sealey JE: Prorenin secretion from human placenta perfused in vitro. Am. J. Physiol (Endocrinol Metab) 23:E876-E882, 1991.

315. von Lutterotti N, Camargo MJF, Campbell Jr WG, Muller FB, Timmermans PB, Sealey JE, Laragh JH: Angiotensin II-receptor antagonist delays renal damage and stroke in salt-loaded Dahl S rats. J. Hypertens. 10: 949-957,1992.

316. Devereux RB, Koren MJ, deSimone G, Roman MJ, Laragh JH: Left ventricular mass as a measure of preclinical hypertensive disease. Am. J. Hypertens. 5:6, Part2, 175S-181S, 1992.

317. Gahnem F, Sealey JE, Atlas SA, Laragh JH: Inhibition of human renin by rat plasma: rat angiotensinogen is a competitive inhibitor of the human renin-substrate interaction. Am. J. Hypertens. 5: 495-501, 1992.

318. Ganau A, Devereux RB, Roman MJ, diSimone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. Studies in Hypertension 19:7, 1550-1558,1992.

319. Devereux RB, Laragh JH: Angiotensin converting enzyme inhibition of renin system activity induces reversal of hypertensive target organ changes: Do these effects predict a reduction in long-term morbidity? Am. J. Hypertens. 5:923-925, 1992.

320. Blumenfeld JD, Cohen N, Laragh JH, Ruggiero DA: Hypertension and catecholamine biosynthesis associated with a glomus jugulare tumor. New Eng. J. Med. 327:894, 1992.

321. Cody RJ, Kubo SH, Laragh JH, Atlas SA. Cardiac secretion of atrial natriuretic factor with exercise in chronic congestive heart failure patients. J. Applied Physiol. 73 (4) 1637-1643, 1992.

322. Kubo SH, Atlas SA, Laragh JH, Cody RJ: Maintenance of forearm vasodilator action of arterial natriuretic factor in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J. Cardiol 69:1306-1309, 1992.

323. Laragh JH: Association of high plasma renin values with white males, greater variability of blood pressure and greater risk of myocardial infarction in hypertensive patients over age 50. High Blood Pressure & Cardio. Prevention 106-108, 1992

324. DeSimone G, Devereux RB, Camargo MJF, Volpe M, Wallerson DC, Atlas SA, Laragh JH: In vivo left ventricular anatomy in rats with two-kidney one-clip and one-kidney, one-clip renovascular hypertension. J. Hypertens. 10: 8, 725-732, 1992.

325. August P, Lenz T, Laragh JH: Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. Am. J. Hypertens. 6: 148S-154S, 1993.

326. Camargo MJF, von Lutterotti N, Campbell Jr WG, Pecker MS, James GD, Timmermans PB, Laragh JH: Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J. Hypertens. 11:31-40, 1993.

327. Phillips GB, Jing T-T, Resnick LM, Barbagallo M, Laragh JH, Sealey JE: Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens. 11: 699-702,1993.

328. Zayas V M, Blumenfeld JD, Bading B, McDonald M, James GD, Lin Y-F, Sharrock NE, Sealey JE, Laragh JH: Adrenergic regulation of renin secretion and renal hemodynamics during deliberate hypotension in man. Am. J. Physiol. 265: F686-F692, 1993.

329. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH: Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation 89: 458-470,1994.

330. Sealey JE, Itskovitz-Eldor J, Rubattu S, James GD, August P, Thaler I, Levron J, Laragh JH: Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 79: 258-264,1994.

331. Gahnem F, Camargo MJF, von Lutterotti N, Laragh JH, Sealey JE: Angiotensinogen dependency of blood pressure of two high renin hypertensive rat models. Am.J.Hypertens 7: 899-904,1994.

332. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan Jr DE, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick ST, Laragh JH: Diagnosis and therapy of primary hyperaldosteronism. Annals of Internal Medicine. 121: 877-885, 1994.

333. Laragh JH, Meltzer JI. Letter to the Editor: Low urinary sodium and myocardial infarction. Hypertension 27: 155-156, 1995.

334. Sealey JE, Trenkwalder P, Gahnem F, Catanzaro DF, Laragh JH: Plasma renin methodology: inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with the traditional enzymatic PRA assay. (Commentary) J. Hypertens. 13: 27-30,1995.

335. Gahnem F, Camargo MJF, von Lutterotti N, Laragh JH, Sealey JE: Angiotensinogen depletion by high renin levels in hypertensive rats: no evidence for tonic stimulation of angiotensinogen by angiotensin II. J. Hypertens. 13: 91-96,1995.

336. August P, Muller FB, Sealey JE, Edersheim TG: Role of renin-angiotensin system in blood pressure regulation in pregnancy. Lancet 354: 986-897,1995.

337. Phillips GB, Jing T-Y, Sealey JE, Laragh JH: Serum sex hormone levels and renin-sodium profile in men with hypertension. Am. J. Hypertension 8: 626-629,1995.

338. Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH: Low urinary sodium is associated with greater risk of myocardial infraction among treated hypertensive men. Hypertension 25: 1144-1152, 1995.

339. de Simone G, Devereux RB, Camargo MJF, Wallerson DC, Sealey JE, Laragh JH: Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II receptor inhibition. J. Hypertens. 13: 1808-1812, 1995.

340. Campbell Jr WG, Gahnem F, Catanzaro DF, James GD, Camargo MJF, Laragh JH, Sealey JE: Plasma and renal prorenin/renin, renin mRNA, and blood pressure in Dahl salt-sensitive and salt-resistant rats. Hypertension 27: 1121-1133, 1996.

341. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu L, Laragh JH. Specific prorenin/renin binding (ProBP) identification and characterization of a novel membrane site. Am. J. Hypertens. 9: 491-502,1996.

342. Sealey JE, Laragh JH. Renin and prorenin: advances and declines in methodology. Clin. Chem. 42: (6) 1-2,1996.

343. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell Jr WG, Feuerstein GZ: Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J. Pharmacol. Exp. Ther. 279: 948-955, 1996.

344. Trenkwalder P, James GD, Laragh JH, Sealey JE: Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am. J. Hypertens. 9: 621-627, 1996.

345. deSimone G, Devereux RB, Volpe M, Camargo MJF, Wallerson DC, Laragh JH: Midwall LV mechanics in rats with or without renovascular hypertension: effect of different Na+ intakes. Am. J. Physiol. 270: (Heart Circ. Physiol. 39) H628-H637, 1996.

346. Laragh JH, Held C, Messerli F, Pepine C, Sleight P: Calcium antagonists and cardiovascular prognosis: A homogeneous group? Am. J. (A Round Table Discussion) Hypertension 9: 99-109, 1996.

347. Laragh JH: The calcium channel blocker debate (Dr. Laragh opinion) Journal of Myocardial Ischemia 8: 109, 1996.

348. Fine EJ, Blaufox MD, Blumenfeld JD, Laragh JH, Cheun KJ, Heller SL, Bongiovanni JA: Exercise renography in untreated subjects with essential hypertension. Journal of Nuclear Medicine 37: 838-842,1996.

349. Sealey JE, Catanzaro DF, Laragh JH: On Plasma Renin Testing (Letter) Clin. Chem. 43: 695-697, 1997.

350. Alderman MH, Ooi W-L, Cohen H, Madhavan S, Sealey JE, Laragh JH: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. 10: 1-8, 1997.

351. Alderman MH, Sealey JE, Cohen H, Madhavan S, Laragh JH: Urinary sodium excretion and myocardial infarction in hypertensive patients: a prospective cohort study. Am. J. Nutr. 65(Suppl): 682S-686S, 1997.

352. Hu L, Catanzaro DF, Pitarresi T-M, Laragh JH, Sealey JE: Identical hemodynamic and hormonal responses to fourteen day infusions of renin or Ang II in conscious rats. J. Hypertens. 16: 1285-1298, 1998.

353. Yan Y, Hu L, Chen R, Sealey JE, Laragh JH, Catanzaro DF: Appropriate regulation of human renin gene expression and secretion in 45-kb human renin transgenic mice. Hypertension 32: 205-214, 1998.

354. Yan Y, Chen R, Pitarresi T-M, Sigmund CD, Gross KW, Sealey JE, Laragh JH, Catanzaro DF: Kidney is the only source of human plasma renin in 45kb hREN transgenic mice. Circ. Res. 83: 1279-1288, 1998.

355. Blumenfeld JD, Laragh JH: Renin system analysis: a rational approach for the diagnosis and treatment of the individual patient with hypertension. Am. J. Hypertens. 11: 894-896, 1998.

356. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August PA, Pickering TG, Laragh JH: Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens. 12: 451-459, 1999.

357. Catanzaro DF, Chen R, Yan Y, Sealey JE, Laragh JH: Appropriate regulation of renin and blood pressure in 45kb human renin/human angiotensinogen transgenic mice. Hypertension 33: (pt 2): 318-322, 1999.

358. Hu L, Catanzaro DF, Laragh JH, Sealey JE: Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats. J. Hypertens 17: 1443-1450,1999.

359. Devereux RB, Case DB, Alderman MH, Pickering TG, Chien S, Laragh JH: Possible role of increased blood viscosity in the hemodynamics of systemic hypertension. Am. J. Cardiol. 85: 1265-1268, 2000.

360. Blumenfeld JD, Sealey JE, Alderman MH, Cohen H, Lappin R, Catanzaro DF, Laragh JH: Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am. J. Hypertens, 13: 855-863, 2000.

361. Laragh JH, Sealey JE: K+ depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. Hypertension 37:806-810, 2001.

362. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am. J. Hypertens. 14: 1154-1167, 2001.

363. Laragh, JH (2001): Laragh?s 25 Lessons in Pathophysiology and 12 Clinical Pearls for Treating Hypertension: Closing Summary, Summary Abstract, and Table of Contents: American Journal of Hypertension. December 2001;14:1173-1177.

364. Laragh, JH (2002): Laragh?s Lessons in Renin System Pathophysiology for Treating Hypertension and its Fatal Cardiovascular Consequences. Elsevier Science Inc., New York, NY (To order, 1-800-545-2522; or www.us.elsevierhealth.com or amazon.com [books/Laragh]).

365. Laragh JH, Sealey JE: Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. AM. J. Hypertens. 16:407-415, 2003.

366. Alderman MH, Cohen HW, Sealey JE, Laragh JH: Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am. J. Hypertens. 17: 1-7, 2004.


SELECTED REVIEWS, BOOK CHAPTERS AND CONCEPTUAL SYNTHESES

1. Laragh, JH, Baer L, Brunner HR, B?hler FR, Sealey JE, Vaughan Jr ED: Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am. J. Med. 52:633-652, l972.

2. Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: The use of renin and aldosterone profiles. Am. J. Med. 55: 26l-274, l973.

3. Laragh, JH, Sealey JE: The renin-angiotensin-aldosterone hormonal system and regulation of sodium, potassium, and blood pressure homeostasis. In: American Physiological Society Handbook of Physiology-Renal Physiology, J. Orloff and R.W. Berliner (Eds.), Waverly Press Inc., Maryland, pp. 83l-908, l973.

4. Sealey JE, Laragh JH: Proposed cybernetic system for sodium and potassium homeostasis: Coordination of aldosterone with changes in intrarenal physical factors. Kidney International 6: 281 290, 1974.

5. Laragh JH, Sealey JE, Buhler FR, Vaughan ED, Brunner HR, Gavras H, Baer L: The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am. J. Med. 58: 4-13, 1975.

6. Krakoff L, Laragh JH: The renin system in the diagnosis of hypertension. Directions in Cardiovascular Medicine. Published by Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J, l977.

7. Sealey, JE, Atlas SA, Laragh JH: Prorenin and other large molecular weight forms of renin. Endocrine Reviews l:365-39l, l980.

8. Laragh JH: The renin-aldosterone axis in hypertension. Textbook of Endocrinology. Edited by Robert H. Williams, MD, W.B. Saunders Co., Philadelphia, pp. l064-l079, l98l.

9. Laragh JH: Position paper: The renin-angiotensin-aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyze different forms of hypertension. In: Frontiers in Hypertension Research, J.H. Laragh, F.R. B?hler, D.W. Seldin (Eds.), Springer-Verlag, New York, pp. l83-l94, l98l.

10. Laragh, JH: Position paper: Hypertension, vasoconstriction, and the causation of cardiovascular injury: The renin-sodium profile as an indicator of risk. In: Frontiers in Hypertension Research, J.H. Laragh, F.R. B?hler, D.W. Seldin (Eds.), Springer-Verlag, New York, pp. 383-395, l98l.

11. Laragh JH, Sealey JE, Niarchos AP, Pickering TG: The vasoconstriction-volume spectrum in normotension and in the pathogenesis of hypertension. Federation Proceedings 4l: 24l5-2423, l982

12. Laragh JH: Amiloride, a potassium-sparing agent new to the U.S.A. Mechanisms and Clinical Relevance. Current Therapeutic Research 32: 173-188, 1982.

13. Laragh JH, Pecker MS: Dietary sodium and essential hypertension: Some myths, hopes, and truths. Ann. Intern. Med. 98:735-743, l983.

14. Brown JJ, Lever AF, Robertson JIS, Semple PR, Bing RF, Heagerty AM, Swales JE, Thurston H, Lendingham JGG, Laragh JH, Hansson L, Nicholls JG, Espiner AE: Salt and Hypertension. Lancet 2:456, l984.

15. Laragh JH: Concept of anti-renin system therapy. An Historic Perspective. Am. J. Med. 77 (2A):l-6, l984.

16. Pickering TG, Sos TA, Laragh JH: Role of balloon dilatation in the treatment of renovascular hypertension. Am. J. Med. 77 (2A): 6l-66, l984.

17. Laragh JH: The meaning of plasma renin measurements: renin and sodium volume-mediated (low renin) forms of vasoconstriction in experimental and human hypertension and in the oedematous states of nephrosis and heart failure. J. Hypertens. 2 (Suppl l):l4l-l40, l984.

18. Resnick LM, Laragh JH: Renin, calcium metabolism and the pathophysiologic basis of antihypertensive therapy. Am. J. Cardiol. 56:68H-74H, l985.

19. Vaughan Jr ED, Case DB, Pickering TG, Sosa RE, Sos TA, Laragh JH: Renovascular Hypertension. Current Trends in Urology, Volume 3, edited by Resnick M.I., 69089, l985.

20. Laragh JH: Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure and electrolyte homeostasis. N. Engl. J. Med. 3l3 (2l):l330-1340, l985.

21. Laragh JH: Renovascular hypertension: A paradigm for all hypertension. J. Hypertens. (Suppl 4): S79-S88, l986.

22. Sealey JE, Glorioso N, Itskovitz J, Laragh JH: Prorenin as a reproductive hormone. Am. J. Med. 8l:l04l-l946, l986.

23. Laragh JH: The endocrine control of blood volume, blood pressure and sodium balance: Atrial hormone and renin system interactions. Journal of Hypertension, 4 (Suppl 2): Sl43-Sl56, (1986).

24. Laragh JH: Endocrine mechanisms in congestive failure: Renin, aldosterone, and atrial natriuretic hormone. Drugs 32: Suppl 5, pp. l-l2, (1986).

25. Laragh JH: Two forms of vasoconstriction in systemic hypertension. Am. J. Cardiol. 60:82G-93, l987.

26. Laragh JH: Spironolactone for Treatment of Hypertension or Congestive Heart Failure: A Review. Excerpta Medica: Princeton, N.J., (1987).

27. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: Presidential Address International Society of Hypertension. On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. Journal of Hypertension 6:763-777, (1988).

28. Pickering TG, James GD, Boddie C, Harshfield G, Blank S, Laragh JH: How common is white coat hypertension? JAMA 259:2 225-228, 1988.

29. Laragh JH, Lamport B, Sealey JE, Alderman MH: Diagnosis ex juvantibus: Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension l2:223-226, l988.

30. Laragh JH, Atlas SA. Atrial natriuretic hormone: A regulator of blood pressure and volume homeostasis. Kidney International 34 (Suppl. 25):S64-S7l, (1988)

31. Laragh JH, Resnick LM: Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney International 34 (Suppl 25): Sl62-Sl74, (1988).

32. Laragh JH: The renin system and the impact of ACE inhibition for understanding, diagnosis, and treatment of hypertension. In: New Frontiers in Cardiovascular Therapy. Eds: Sonnenblick, E.H., J.H. Laragh, and M. Lesch. Excerpta Medica, Princeton, New Jersey, p. 84-116, 1989.

33. Laragh JH: Issues, goals, and guidelines in selecting first-line drug therapy for hypertension. Hypertension 13 (Suppl I): I-103-I-112, 1989.

34. Laragh JH: Extrarenal tissue prorenin systems do exist. Are intrinsic vascular and cardiac tissue renin fact or fancy? Am. J. Hypertens. 2:262-265, l989.

35. Laragh JH: Hypertension, In: The World Book Encyclopedia, Vol. H, No. 9, World Book Encyclopedia Publishers, Chicago, (1989).

36. Laragh JH, Sealey JE: The renin-angiotensin-aldosterone system in hypertensive disorders: A key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. 1239-1348, 1990.

37. Sealey JE, Laragh JH: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. 1287-1317, 1990.

38. M?ller FB, Laragh JH: Clinical evaluation and differential diagnosis of the individual hypertensive patient. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. 1385-1396, 1990.

39. M?ller FB, Laragh JH: Issues, goals, and guidelines for choosing first-line and combination antihypertensive drug therapy. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. 2107-2115, 1990.

40. Sealey JE, Laragh JH: The integrated regulation of electrolyte balance and blood pressure by the renin system. In: The Regulation of Sodium and Chloride Balance. Eds. D.W. Seldin and G. Giebisch, Raven Press, New York, pp. 133-193, 1990.

41. Laragh JH, Sealey JE: The renin system and its pathophysiology in disease. In: The Regulation of Sodium and Chloride Balance. Eds. D.W. Seldin and G. Giebisch, Raven Press, New York, pp. 195-234, 1990.

42. Laragh JH: Rationale for individualized therapies. In: Handbook of Hypertension: The Management of Hypertension, Vol. 13. Ed. F.R. B?hler and J.H. Laragh. Elsevier Science Publishers, New York pp. 379-410, 1990.

43. B?hler FR, Laragh JH: (Eds.) Handbook of Hypertension: Vol. 13: The Management of Hypertension, Elsevier Science Publishers, New York, 1990.

44. Laragh JH: Hypertension, In: The World Book Encyclopedia, Vol. H, No. 9, World Book Encyclopedia Publishers, Chicago, 1990.

45. Atlas SA, Laragh JH: Atrial natriuretic factor and its involvement in hypertensive disorders. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. 86l-883, (1990).

46. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. In: -Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. l089-ll03, (1990).

47. Laragh JH, Sealey JE: The renin-angiotensin-aldosterone system in hypertensive disorders: A key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Hypertension: Pathophysiology, Diagnosis and Management. Eds. J.H. Laragh and B.M. Brenner, Raven Press, New York, pp. l239-l348, (1990).

48. Laragh JH, Pickering TG: Essential Hypertension. In: The Kidney 4th Ed. Eds. B.M. Brenner and F.C. Rector, Jr. W.B. Saunders Company, Philadelphia, pp. 1909-1939, 1991.

49. Pickering TG, Laragh JH: Renovascular Hypertension. In: The Kidney 4th Ed. Eds. B.M. Brenner and F.C. Rector, Jr. W.B. Saunders Company, Philadelphia pp. 1940-1967, 1991.

50. Laragh JH: Perspectives on the discovery process in medical research. New Perspectives in Health Care Economics. Eds. U.E. Reinhardt, F.J. Pinto. Princeton University & Bristol-Myers Squibb, MEDIQ, Ltd., London 1991.

51. Laragh JH, Sealey JE: Renin-angiotensin-aldosterone system and the renal regulation of sodium, potassium, and blood pressure homeostasis. In: Handbook of Renal Physiology 2nd ed. Ed. E.E. Windhager. Oxford University Press, New York, pp. 1409-1541, 1992.

52. Atlas SA, Cody RJ, Laragh JH: Atrial natriuretic peptide in heart failure. Braunwald Heart Disease Textbook of Cardiovascular Medicine. Update, 4th Ed., No. 2. W.B. Saunders, Philadelphia pp. 19-40, 1992.

53. Laragh JH: The renin system and four lines of hypertension research: Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, the prorenin and heart attack. Lewis K. Dahl Memorial Lecture. Hypertension 20:3, 267-279. 1992.

54. Laragh JH: Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Intl. 44:1163-1175, (1993).

55. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan Jr DE, Sos TA, Atlas SA, M?ller FB, Acevedo R, Ulick ST, Laragh JH: Diagnosis and therapy of primary hyperaldosteronism. Annals of Internal Medicine 122: 877-885, 1994.

56. Tobian L, Brunner HR, Cohn JN, Gavras H, Laragh JH, Materson BJ, Weber MA: Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ form the JNC V consensus guideline. Am. J. Hypertens. Special Article 7: 859-872, 1994.

57. Laragh JH: Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J. of Human Hypertens. 9: 385-390, 1995.

58. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: Nephron heterogeneity with unsuppressible renin secretion: a cause of essential hypertension. Chapter 84: Hypertension: Pathophysiology, Diagnosis and Management, Second Edition. Edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

59. Sealey JE, Laragh JH: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. Chapter 105: In Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. Edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

60. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH: Renin is not synthesized by cardiac and extrarenal vascular tissues: A review of experimental evidence. Chapter 106: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition: Edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

61. Laragh JH, Sealey JE: Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best -fit drug regimen. Chapter 107: Hypertension: Pathophysiology, Diagnosis and Management, Second Edition edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

62. Sealey JE, von Lutterotti N, Rubattu S, Campbell Jr WG, Gahnem F, Halimi J-M, Laragh JH: The greater renin system its prorenin-directed vasodilator limb: relevance to diabetes mellitus, pregnancy, and hypertension. Chapter 111: Hypertension: Pathophysiology Diagnosis and Management, Second Edition, Edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

63. Blumenfeld JD, Mann SJ, Laragh JH: Clinical evaluation and differential diagnosis of the individual hypertensive patient. Chapter 112: In Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. Edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

64. Sealey JE, James GD, Laragh JH: Interpretation and guidelines for the use of plasma and urine aldosterone and plasma angiotensin II, angiotensinogen, prorenin, peripheral and renal vein renin tests. Chapter 116: In Hypertension: Pathophysiology, Diagnosis and Management Second Edition: Edited by J.H. Laragh and B.M. Brenner. Raven Press, Ltd. New York 1995.

65. Mann SJ, Blumenfeld JD, Laragh JH: Issues, goals and guidelines for choosing first-line and combination antihypertensive drug therapy. Chapter 150: Hypertension: Pathophysiology, Diagnosis and Management, Second Edition, edited by JH Laragh and BM Brenner. Raven Press, Ltd. New York 1995.

66. Laragh JH: Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J. Human Hypertension 9:385-390, 1995.

67. Laragh JH: Lasix: Reaches a watershed: Thirty years of clinical use. Cardiovascular Review & Reports 17: 23-33, 1996.

68. Laragh JH. Sealey JE: Causal roles of plasma renin in hypertension and in heart attack, heart failure, stroke and kidney failure and the unique value of anti-renin system drugs in prevention and treatment. In Renin Angiotensin. Edited by H.R. Ulfendahl and M. Aurell, Chapter 22: pp 273-305: Wenner Gren International Series. Portland Press, London 1998.

69. Laragh JH, Sealey JE: The renin-angiotensin-aldosterone system: personal reflections. Pp 46-53. In 100 Years of the Renin Angiotensin System: Edited by M. Gary Nicholls, Hans R. Brunner, Hamid Ikram, Charles S. Sweet & J. Findlay Walker, Merck and Co. Inc., Whitehouse Station, N.J, Pages 46-53, 1998.

70. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am. J. Hypertens. 14: 1154-1167, 2001.

71. Laragh JH, Sealey JE: K+ depletion and the progression of hypertensive disease or heart failure: the pathogenic role of diuretic-induced aldosterone secretion. Hypertension 37: 806-810, 2001.

72. Laragh JH: Laragh's 25 Lessons in Pathophysiology and 12 Clinical Pearls for Treating Hypertension: Closing Summary, Summary Abstract, and Table of Contents: American Journal of Hypertension. (December) 2001; 14:1173-1177.

73. Laragh?s Lessons in Pathophysiology and Clinical Pearls for Treating Hypertension: Introduction: Treatment of Hypertension is a worldwide failure. Am. J. Hypertens. 14:84-89, (January) 2001.

74. Laragh?s Lesson I: A Brief History of Hypertension Research Renin is Twice Rejected. Lesson II: Insights from studies of malignant hypertension. Lesson III: How the renin system works: tiny amounts of infused angiotensin cause and sustain hypertension in humans: noradernaline dose not. Lesson IV: The nomogram: plasma renin levels respond to how much salt we eat. Lesson V: The abnormal plasma renin levels in essential hypertension. Lesson VI: The plasma renin system is the servocontrol for blood pressure and sodium and potassium balance. Am. J. Hypertens. 14:186-194, (February) 2001.

75. Laragh?s Lesson VII: Three pharmacologic ways to block the circulating renin-angiotensin-aldosterone system and lower pressure in hypertensive patients. Lesson VIII: Proof that excess plasma renin-angiotensin causes malignant hypertension and its fatal cardiac, cerebral, and renal vasculitis. Lesson IX: Milder excesses of plasma renin-angiotensin cause and sustain medium and high renin essential hypertension (70% of essential hypertension). Am. J. Hypertens. 14:296-304, (March) 2001.

76. Laragh?s Lesson X: Inappropriately high plasma renin levels that sustain medium and high renin essential hypertension are also associated with later heart attacks or strokes not observed in low renin essential hypertension. Lesson XI: Low renin essential hypertension is sodium mediated and lacks subsequent cardiovascular sequelae. Lesson XII: Confirmations from clinical trials in cardiology and nephrology: only anti-renin system drugs arrest progression of cardiac or diabetic or nondiabetic renal disease. Am. J. Hypertens. 14:307-310 (April) 2001.

77. Laragh?s Lesson XIII: The great salt debate: is dietary sodium hazardous to your health? An epidemiologic hypothesis without the evidence. Lesson XIV: On the physiology and pathophysiology of sodium ions and their relevance to blood pressure levels. Lesson XV: Poiseuille?s law applied to renin system behavior creates the volume-vasoconstriction equation that supports all normotension or hypertension. Am. J. Hypertens. 14:397-404 (May) 2001.

78. Laragh?s Lesson XVI: How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. Lesson XVII: A functional physiologic classification of commonly available V and R types of antihypertensive drugs. Lesson XVIII: Summary of Lessons XVI ? XVII. Am. J. Hypertens. 14:491-503 (June) 2001.

79. Laragh?s Lesson XIX: On the power of plasma renin and angiotensin levels. Lesson XX: The history of plasma renin testing. Lesson XXI: Procedural and technical guidelines. Lesson XXII: How to interpret plasma renin values. Lesson XXIII: A model clinical report for the plasma renin test in hypertensive patients. Am. J. Hypertens. 14:603-609 (July) 2001.

80. Laragh?s Lesson XXIV: On the major roles of the renin system in the pathogenesis of hypertension and its sequelae, heart attack, heart failure, kidney failure, and stroke: replies to commonly asked questions. Am. J. Hypertens. 14:733-742 (August) 2001.

81. Laragh?s Lesson XXV: How to mechanistically diagnose and correctly treat a hypertensive crisis. Am. J. Hypertens. 14:837-854 (September) 2001.

82. Laragh Lessons in Renin System Pathophysiology for Treating Hypertension and its Fatal Consequences. Elsevier Sciences Inc. 2002, New York, NY (To order: 1-800-545-2522 or www.us.elsevierhealth.com). (Above references 71-80 updated and formatted for this book).

83. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am. J. Hypertens. 16:407-415, 2003.

84. Alderman MH, Cohen HW, Sealey JE, Laragh JH: Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am. J. Hypertens. 17: 1-7, 2004.